GlassScriptPhysician profile
Suneya Hogarty
NPI 1366407686
$46,665.77
in general payments reported to CMS, 2019-2025
36 companies · $2,669 in 2025
The $2,669 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,521 · 2020: $20K · 2021: $5,136 · 2022: $2,290 · 2023: $4,401 · 2024: $2,388 · 2025: $2,669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,623 · Consulting Fee: $1,620 · Education: $216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,622.55 |
| Consulting Fee | $1,620.00 |
| Education | $215.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Rheumatology | $28,750.00 | 2019-2021 | |
| Janssen Biotech, INC. | $3,293.14 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Amgen INC. | $2,879.45 | 2019-2025 | Enbrel, Krystexxa, Otezla |
| Horizon Therapeutics Plc | $1,604.20 | 2019-2023 | Krystexxa |
| Ucb, INC. | $1,601.36 | 2019-2025 | Cimzia, Bimzelx |
| Abbvie INC. | $1,346.48 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,076.99 | 2019-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $821.63 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $784.68 | 2021-2025 | Saphnelo, Evusheld |
| Mallinckrodt Hospital Products INC. | $717.70 | 2020-2025 | Acthar |
| Pfizer INC. | $493.51 | 2019-2025 | |
| Lilly USA, LLC | $429.30 | 2020-2025 | Taltz, Zepbound, Olumiant |
| Aurinia Pharma U.S., INC. | $348.22 | 2021-2025 | Lupkynis |
| Genentech USA, INC. | $342.80 | 2019-2024 | Actemra |
| Genzyme Corporation | $292.61 | 2019-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $227.07 | 2024-2025 | |
| Actelion Pharmaceuticals US, INC. | $223.09 | 2020-2023 | Opsumit |
| Radius Health, INC. | $193.62 | 2019-2025 | Tymlos |
| Organon LLC | $192.39 | 2021-2025 | Hadlima, Nexplanon |
| E.R. Squibb & Sons, L.L.C. | $157.79 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.27 | 2020-2025 | Ofev, Cyltezo |
| Hikma Pharmaceuticals USA | $127.71 | 2019-2023 | Mitigare |
| Regeneron Healthcare Solutions, INC. | $121.50 | 2019-2020 | |
| Fidia Pharma USA INC. | $103.01 | 2019-2024 | Triluron, Hymovis, Hyalgan |
| Fresenius Kabi USA, LLC | $102.97 | 2023 | Idacio |
| Celgene Corporation | $67.12 | 2019 | |
| Scilex Pharmaceuticals INC. | $47.02 | 2024 | |
| Ani Pharmaceuticals, INC. | $35.64 | 2024 | Purified Cortrophin Gel |
| Sandoz INC. | $33.57 | 2023 | Hyrimoz |
| Mallinckrodt Enterprises LLC | $20.25 | 2019 | |
| Sanofi-Aventis U.S. LLC | $17.32 | 2022 | |
| Medexus Pharma, INC. | $15.34 | 2019 | |
| Alexion Pharmaceuticals, INC. | $13.92 | 2020 | |
| Merck Sharp & Dohme LLC | $13.50 | 2019 | |
| Biocryst Pharmaceuticals, INC. | $12.48 | 2020 | |
| Depuy Synthes Sales INC. | $11.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suneya Hogarty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.